Verve Therapeutics(VERV) Newsfilter·2025-01-13 12:00Core Insights - Verve Therapeutics is advancing a new class of genetic medicines targeting cardiovascular diseases, with significant milestones expected in 2025 [2][3][4] Pipeline Updates - Initial data for the Heart-2 Phase 1b clinical trial of VERVE-102, targeting PCSK9, is anticipated in the second quarter of 2025 [4][5] - The Heart-2 trial includes patients with heterozygous familial hypercholesterolemia (HeFH) and premature coronary artery disease (CAD), with dosing having progressed to the 0.6 mg/kg cohort [4][5] - VERVE-301 has been nominated as a development candidate targeting the LPA gene, with a milestone payment expected from Eli Lilly [2][6] - The company plans to initiate a Phase 2 clinical trial for the PCSK9 program in the second half of 2025 [5] Financial Position - Verve Therapeutics is well-capitalized, with a cash runway extending into mid-2027, supported by existing cash and a milestone payment from Eli Lilly [2][6] Upcoming Events - The company will present at the 43rd Annual J.P. Morgan Healthcare Conference on January 15, 2025 [2][7] Company Overview - Verve Therapeutics is focused on developing genetic medicines that aim to provide lifelong cholesterol lowering after a single treatment, targeting key drivers of high cholesterol [3][8] - The lead programs include VERVE-102, VERVE-201, and VERVE-301, which address LDL-C, remnant cholesterol, and Lp(a) respectively [8][9]